Small molecule inhibitors of Wnt/β-Catenin/Lef-1 Signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo

Neoplasia

Volumn 12, Issue 4, 2010, Pages 326-335

  Gandhirajan, Rajesh Kumar ^a   Staib, Peter Anton ^a   Minke, Katharina ^a   Gehrke, Iris ^a   Plickert, Günther ^a   Schlösser, Axel ^b   Schmitt, Esther Katharina ^c   Hallek, Michael ^a   Kreuzer, Karl Anton ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Novartis Pharma Inc   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BETA CATENIN; CGP 049090; LYMPHOID ENHANCER FACTOR 1; PKF 115 584; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LC 50; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TOXICITY TESTING; TUMOR XENOGRAFT;

EID: 77951675861     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91972     Document Type: Article

References (35)

1. Caligaris-Cappio F, Gottardi D, Alfarano A, Stacchini A, Gregoretti MG, Ghia P, Bertero MT, Novarino A, and Bergui L (1993). The nature of the B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells 19, 601-613.
2. Hanada M, Delia D, Aiello A, Stadtmauer E, and Reed JC (1993). Bcl-2 genehypo-methylation and high-level expression in B-cell chronic lymphocytic-leukemia. Blood 82, 1820-1828.
3. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, and Carson DA (2004). Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 101, 3118-3123.
4. Reya T and Clevers H (2005). Wnt signalling in stem cells and cancer. Nature 434,843-850.
5. Moon RT, Kohn AD, De Ferrari GV, and Kaykas A (2004). WNTand β-catenin signalling: diseases and therapies. Nat Rev Genet 5, 691-701.
6. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, and Kinzler KW (1998). Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512.
7. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, and Ben-Ze'ev A (1999). The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96, 5522-5527.
8. Tetsu O and McCormick F (1999). β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426.
9. Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW, Henkart PA, Bottaro DP, Soon L, Bonvini P, et al. (2002). Regulation of leukemic cell adhesion, proliferation, and survival by β-catenin. Blood 100, 982-990.
10. Dosen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, and Rian E (2006). Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol 29, 7-13.
11. Grosschedl R (2000). Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 13, 15-24.
12. Hovanes K, Li TWH, Munguia JE, Truong T, Milovanovic T, Marsh JL, Holcombe RF, and Waterman ML (2001).β-Catenin-sensitiveisoformsoflymphoidenhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28, 53-57.
13. Howe D and Bromidge T (2006). Variation of LEF-1 mRNA expression in low- grade B-cell non-Hodgkin's lymphoma. Leuk Res 30, 29-32.
14. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu YH, Lepre J, Shah N, and Kay NE (2003). Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 1, 346-361.
15. Klein U, Tu YH, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, et al. (2001). Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194, 1625-1638.
16. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, and Shivdasani RA (2004). Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5, 91-102.
17. Loisel S, Le Ster K, Quintin-Roue I, Pers JO, Bordron A, Youinou P, and Berthou C (2005). Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leuk Res 29, 1347-1352.
18. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia- Manero G, Manshouri T, and Albitar M (2002). Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16, 1045-1052.
19. Caligaris-Cappio F (2003). Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 123, 380-388.
20. Ghia P, Granziero L, Chilosi M, and Caligaris-Cappio F (2002). Chronic B cell malignancies and bone marrow microenvironment. Sem Cancer Biol 12, 149-155.
21. Christian SL, Sims PV, and Gold MR (2002). The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J Immunol 169, 758-769.
22. Zhou FF, Zhang L, Gong K, Lu GY, Sheng BY, Wang AJ, Zhao NM, Zhang XF, and Gong YD (2008). LEF-1 activates the transcription of E2F1. Biochem Biophys Res Commun 365, 149-153.
23. Kelman Z (1997). PCNA: structure, functions and interactions. Oncogene 14, 629-640.
24. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, and Dang CV (2003). An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4, R69.1-R69.10.
25. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, and Li F (2006). The c-Myc target gene network. Semin Cancer Biol 16, 253-264.
26. Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, Schlosser A, Schmitt EK, Hallek M, and Kreuzer KA (2009). Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 82,165-175.
27. Janicke RU, Sprengart ML, Wati MR, and Porter AG (1998). Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273, 9357-9360.
28. Korfali N, Ruchaud S, Loegering D, Bernard D, Dingwall C, Kaufmann SH, and Earnshaw WC (2004). Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis. J Biol Chem 279, 1030-1039.
29. Smulson ME (1999). Poly(ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells. Cancer Res 59, 2190-2194.
30. Roue G, Lancry L, Duquesne F, Salaun V, Troussard X, and Sola B (2001). Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia. Leuk Res 25, 967-980.
31. Jones DT, Ganeshaguru K, Virchis AE, Folarin NI, Lowdell MW, Mehta AB, Prentice HG, Hoffbrand AV, and Wickremasinghe RG (2001). Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 98, 2800-2807.
32. Faria JR, Yamamoto M, Faria RM, Kerbauy J, and Oliveira JS (2006). Fludarabine induces apoptosis in chronic lymphocytic leukemia-the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins. Braz J Med Biol Res 39, 327-333.
33. Pepper C, Thomas A, Hidalgo de Quintana J, Davies S, Hoy T, and Bentley P (1999). Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia - the role of Bcl-2 family dysregulation. Leuk Res 23, 1007-1014.
34. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, et al. (1998). Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91, 3379-3389.
35. Chen CL, Tai HL, Zhu DM, and Uckun FM (1999). Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with antileukemic activity. Pharm Res 16, 1003-1009.